Loading...
Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes
Mantle cell lymphoma (MCL) is an incurable, typically aggressive subtype of non-Hodgkin lymphoma, accounting for 4%–7% of newly diagnosed non-Hodgkin lymphoma cases. Chemoresistance commonly ensues in MCL, and patients with this heterogeneous disease invariably relapse, underscoring the unmet need f...
Na minha lista:
| Udgivet i: | Ther Clin Risk Manag |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4644179/ https://ncbi.nlm.nih.gov/pubmed/26609233 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S72943 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|